Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Postmenopausal Women With ER+ HER2- Primary Breast Cancer”

6 trials

Showing 6 of 6 results

Early research (Phase 1)Study completedNCT03236974
What this trial is testing

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Who this might be right for
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
AstraZeneca 49
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Large-scale testing (Phase 3)Study completedNCT02422615
What this trial is testing

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 726
Not applicableStudy completedNCT02753686
What this trial is testing

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Who this might be right for
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Novartis Pharmaceuticals 440
Testing effectiveness (Phase 2)UnknownNCT00931450
What this trial is testing

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Institut Català d'Oncologia 70

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation